

- with lymph node positive breast carcinoma entered on two prospective clinical trials. *Cancer* 1996;78(4):764–72.
4. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, *et al.* Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. *Breast Cancer Res Treat* 1997;45(3):241–9.
 5. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, *et al.* Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods. *Breast Cancer Res Treat* 1995;34(3):221–8.
 6. Biesterfeld S, Schroder W, Steinhagen G, Koch R, Veuskens U, Schmitz FJ, *et al.* Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. *Anticancer Res* 1997;17(6D):4723–9.
 7. Katoh AK, Stemmler N, Specht S, D'Amico F. Immunoperoxidase staining for estrogen and progesterone receptors in archival formalin fixed, paraffin embedded breast carcinomas after microwave antigen retrieval. *Biotech Histochem* 1997;72(6):291–8.
 8. Blomqvist C, von Boguslawski K, Stenman UH, Maenpaa H, von Smitten K, Nordling S. Long-term prognostic impact of immunohistochemical estrogen receptor determinations compared with biochemical receptor determination in primary breast cancer. *Acta Oncol* 1997;36(5):530–2.
 9. Huang A, Pettigrew NM, Watson PH. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. *J Pathol* 1996;180(2):223–7.
 10. Pertschuk LP, Kim YD, Axiotis CA, Braverman AS, Carter AC, Eisenberg KB, *et al.* Estrogen receptor immunocytochemistry: the promise and the perils. *J Cell Biochem* 1994;19(Suppl):134–7.
 11. Kerner H, Zilberman M, Israeli E, Lichtig C. A comparative study of radioligand (DCC) and modified immunoperoxidase anti-estrogen receptor techniques in breast carcinoma. *Israel J Med Sci* 1994;30(7):506–9.
 12. Gilliland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. *Proc Natl Acad Sci U S A* 1990;87(7):2725–9.
 13. Becker-Andre M, Hahlbrock K. Absolute mRNA quantification using the polymerase chain reaction (PCR): a novel approach by a PCR aided transcript titration assay (PATY). *Nucleic Acids Res* 1989;17(22):9437–46.
 14. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. *Proc Natl Acad Sci U S A* 1989;86(24):9717–21.

Book Review

Wartofsky L (ed): *Thyroid Cancer: A Comprehensive Guide to Clinical Management*, 800 pp, Totowa, NJ Humana Press (\$175).

As stated by the editor, this is a multi-author textbook intended “to fill the needs of practicing physicians for clinically relevant information about thyroid cancer and to serve as an extensive and inclusive reference source to clinicians managing patients with thyroid cancer.” The book is divided into nine sections that deal with thyroid nodules, thyroid cancer, papillary carcinoma, follicular carcinoma, anaplastic carcinoma, lymphoma, medullary carcinoma, and miscellaneous and unusual cancers of the thyroid. Each section is divided further into chapters that examine clinical aspects, pathology, surgical approach, nuclear medicine and external radiation therapy, chemotherapy, prognosis, and so forth. Such a format facilitates the use of the text as a practical handbook for management, but it also causes numerous overlaps (*e.g.*, cancer in chil-

dren is covered in four different chapters, and there are different chapters that cover prognosis, follow-up, and response to therapy or specific tumor types). Differences of opinion on several issues reflect controversies on the management of thyroid cancer, the absence of prospective studies comparing various surgical and/or post-surgical therapies, and other aspects of thyroid oncology.

As often happens with medical books, the text becomes outdated fast. Most of the references in this book are from 1995 and 1996, except in the chapters that are written by the editor, which are not only up to date but also the most interesting aspects of the book. The book will be of interest to clinicians and pathologists who are involved with thyroid cancer.

Manuel Sobrinho-Simoes
University of Porto
Porto, Portugal